Anna Falanga

Summary

Publications

  1. ncbi Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils
    Anna Falanga
    Hematology Division, Ospedali Riuniti, Largo Barozzi 1, 24128 Bergamo, Italy
    Semin Hematol 42:239-47. 2005
  2. ncbi Cancer and venous thromboembolism
    Andrea Piccioli
    Department of Medical and Surgical Sciences, University of Padua, Padua, Italy
    Semin Thromb Hemost 32:694-9. 2006
  3. pmc Comparative assessment of low-molecular-weight heparins in cancer from the perspective of patient outcomes and survival
    Anna Falanga
    Division of Immunohematology and Transfusion Medicine, Ospedali Riuniti, Bergamo, Italy
    Patient Relat Outcome Meas 2:175-88. 2011
  4. doi Venous thromboembolism in the hematologic malignancies
    Anna Falanga
    Division of Immunohematology and Transfusion Medicine, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Curr Opin Oncol 24:702-10. 2012
  5. doi Coagulation and cancer: biological and clinical aspects
    A Falanga
    Division of Immunohematology and Transfusion Medicine, Ospedali Riuniti, Bergamo, Italy
    J Thromb Haemost 11:223-33. 2013
  6. doi Mechanisms of thrombosis in cancer
    Anna Falanga
    Division of Immunohematology and Transfusion Medicine, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Thromb Res 131:S59-62. 2013
  7. doi Thrombotic disease in the myeloproliferative neoplasms
    Anna Falanga
    Division of Immunohematology and Transfusion Medicine, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Hematology Am Soc Hematol Educ Program 2012:571-81. 2012
  8. ncbi Microparticles in tumor progression
    Anna Falanga
    Division of Immunohematology and Transfusion Medicine, Department of Oncology Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Thromb Res 129:S132-6. 2012
  9. doi Epidemiology, risk and outcomes of venous thromboembolism in cancer
    A Falanga
    Division of Immunohematology and Transfusion Medicine, Department Oncology Hematology, Ospedali Riuniti, Bergamo, Italy
    Hamostaseologie 32:115-25. 2012
  10. doi Anticancer treatment and thrombosis
    Anna Falanga
    Division of Immunohematology and Transfusion Medicine, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Thromb Res 129:353-9. 2012

Detail Information

Publications65

  1. ncbi Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils
    Anna Falanga
    Hematology Division, Ospedali Riuniti, Largo Barozzi 1, 24128 Bergamo, Italy
    Semin Hematol 42:239-47. 2005
    ..Available data suggest that these hemostatic markers deserve to be included in prospective clinical studies aimed at identifying their predictive role in the vascular complications of patients with ET and PV...
  2. ncbi Cancer and venous thromboembolism
    Andrea Piccioli
    Department of Medical and Surgical Sciences, University of Padua, Padua, Italy
    Semin Thromb Hemost 32:694-9. 2006
    ..Anticoagulant drugs appear to be an attractive strategy in cancer treatment because there is growing evidence for their possible benefits in terms of cancer prognosis and patient survival...
  3. pmc Comparative assessment of low-molecular-weight heparins in cancer from the perspective of patient outcomes and survival
    Anna Falanga
    Division of Immunohematology and Transfusion Medicine, Ospedali Riuniti, Bergamo, Italy
    Patient Relat Outcome Meas 2:175-88. 2011
    ..Although the results are controversial, the interest in this research area remains high...
  4. doi Venous thromboembolism in the hematologic malignancies
    Anna Falanga
    Division of Immunohematology and Transfusion Medicine, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Curr Opin Oncol 24:702-10. 2012
    ..This review summarizes the current knowledge of the epidemiology, prophylaxis, and treatment of venous thromboembolism (VTE) in patients with lymphoma, multiple myeloma or acute leukemia...
  5. doi Coagulation and cancer: biological and clinical aspects
    A Falanga
    Division of Immunohematology and Transfusion Medicine, Ospedali Riuniti, Bergamo, Italy
    J Thromb Haemost 11:223-33. 2013
    ..We also review the assessment of the risk of thrombohemorrhagic events in cancer patients, and the prophylaxis and treatment of such manifestations...
  6. doi Mechanisms of thrombosis in cancer
    Anna Falanga
    Division of Immunohematology and Transfusion Medicine, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Thromb Res 131:S59-62. 2013
    ..In this review we provide an overview of the principal mechanisms of thrombosis in cancer, including clinical and biological risk factors, and a summary of risk assessment tools to predict thrombosis in the single patient...
  7. doi Thrombotic disease in the myeloproliferative neoplasms
    Anna Falanga
    Division of Immunohematology and Transfusion Medicine, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Hematology Am Soc Hematol Educ Program 2012:571-81. 2012
    ..The predictive value of these biomarkers for thrombosis remains to be established to identify subsets of patients at elevated risk who may benefit from prophylaxis with antithrombotic drugs...
  8. ncbi Microparticles in tumor progression
    Anna Falanga
    Division of Immunohematology and Transfusion Medicine, Department of Oncology Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Thromb Res 129:S132-6. 2012
    ..The utility of measuring MP as a diagnostic and prognostic marker is currently a subject of intense investigation. The possibility to inhibit MP production by pharmacological interventions represents a future challenge...
  9. doi Epidemiology, risk and outcomes of venous thromboembolism in cancer
    A Falanga
    Division of Immunohematology and Transfusion Medicine, Department Oncology Hematology, Ospedali Riuniti, Bergamo, Italy
    Hamostaseologie 32:115-25. 2012
    ..In this review the principal aspects of epidemiology, risk factors and outcome of cancer-associated VTE are summarized...
  10. doi Anticancer treatment and thrombosis
    Anna Falanga
    Division of Immunohematology and Transfusion Medicine, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Thromb Res 129:353-9. 2012
    ..Predictive models for VTE in cancer patients are now available and will allow the possibility of improving outcomes for patients under chemotherapy by identifying those who would benefit most from thromboprophylaxis...
  11. ncbi Deep vein thrombosis in cancer: the scale of the problem and approaches to management
    A Falanga
    Department of Hematology Oncology, Ospedali Riuniti, Bergamo, Italy
    Ann Oncol 16:696-701. 2005
    ....
  12. ncbi Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera
    Anna Falanga
    Department of Hematology Oncology, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Exp Hematol 33:523-30. 2005
    ..We want to define whether this phenomenon plays a role in the formation of circulating PMN-platelet aggregates in these conditions...
  13. ncbi Thrombophilia in cancer
    Anna Falanga
    Hematology Oncology Department, Ospedali Riuniti Bergamo, Bergamo, Italy
    Semin Thromb Hemost 31:104-10. 2005
    ..In this article, the various aspects of the complex relationship between thrombosis and cancer, from pathophysiology to therapy, are reviewed...
  14. doi The incidence and risk of venous thromboembolism associated with cancer and nonsurgical cancer treatment
    Anna Falanga
    Department of Hematology Oncology, Hemostasis and Thrombosis Center, Bergamo, Italy
    Cancer Invest 27:105-15. 2009
    ..Therefore, they recommend that all patients hospitalized or bedridden owing to cancer should be considered for thromboprophylaxis in the absence of contraindications to anticoagulant therapy...
  15. ncbi Clotting mechanisms and cancer: implications in thrombus formation and tumor progression
    Anna Falanga
    Experimental Laboratory on Thrombosis, Ospedali Riuniti Bergamo, Largo Barozzi, 1, 24128 Bergamo, Italy
    Clin Adv Hematol Oncol 1:673-8. 2003
    ..Further, pharmacological modulation of malignant cell hemostatic properties may not only affect the tumor-associated thrombotic risk but may also leave open the possibility to interfere with the progression of the disease...
  16. ncbi V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules
    Anna Falanga
    Department of Hematology Oncology, Ospedali Riuniti, Bergamo, Italy
    Exp Hematol 35:702-11. 2007
    ....
  17. ncbi Heparin in tumor progression and metastatic dissemination
    Anna Falanga
    Department of Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Semin Thromb Hemost 33:688-94. 2007
    ..The published data are promising and provide new information in the research knowledge in this field. The potential anticancer activity of heparins is supported by data from in vitro and experimental studies...
  18. doi Hypercoagulability and tissue factor gene upregulation in hematologic malignancies
    Anna Falanga
    Department Hematology Oncology, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Semin Thromb Hemost 34:204-10. 2008
    ..Understanding the pathophysiology of hypercoagulability is critical to the design of appropriate measures for intervention in these hematologic disorders to prevent thromboembolic complications...
  19. ncbi Venous thromboembolism in the hematologic malignancies
    Anna Falanga
    Division of Immunohematology and Transfusion Medicine, Department of Oncology Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy
    J Clin Oncol 27:4848-57. 2009
    ..Large, prospective, randomized clinical trials are needed to establish the best practice for thromboprophylaxis and treatment of VTE in these types of cancers...
  20. ncbi The predictive value of D-dimer measurement for cancer in patients with deep vein thrombosis
    Anna Falanga
    Hematology Division, Hematology Oncology Department, Ospedali Riuniti, Bergamo, Italy
    Haematologica 90:149. 2005
  21. ncbi Tumor cell prothrombotic properties
    A Falanga
    Dept Hematology Oncology, Ospedali Riuniti, Bergamo, Italy
    Haemostasis 31:1-4. 2001
    ..All of the mechanisms are not entirely understood, however research studies in the last ten years have greatly improved our knowledge of tumor-promoted pro-thrombotic functions...
  22. ncbi Effect of all-trans-retinoic acid on the hypercoagulable state of patients with breast cancer
    Anna Falanga
    Department of Hematology, Ospedali Riuniti, Largo Barozzi, 14128 Bergamo, Italy
    Am J Hematol 70:9-15. 2002
    ..However, in the ATRA + Tam groups, hypercoagulation markers were decreased compared with Tam alone. These results suggest that in selected conditions, pre-operative ATRA may modulate the hypercoagulable state of breast cancer patients...
  23. ncbi Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia
    Anna Falanga
    Hematology Oncology Department, Ospedali Riuniti di Bergamo, Largo Barozzi 1, 24128, Bergamo, Italy
    Best Pract Res Clin Haematol 16:463-82. 2003
    ..Special attention is devoted to the use of all-trans-retinoic acid (ATRA), which has revolutionized the treatment of APL and markedly ameliorated the APL-related coagulopathy...
  24. ncbi Coagulopathy of acute promyelocytic leukemia
    A Falanga
    Hematology Oncology Department, Ospedali Riuniti, Largo Barozzi n 1, I 24128 Bergamo, Italy
    Acta Haematol 106:43-51. 2001
    ..Special attention will be devoted to the new therapy with all-trans retinoic acid, which has completely changed the natural history of APL and APL-related coagulopathy...
  25. ncbi All-trans-retinoic acid and bleeding/thrombosis
    Anna Falanga
    Hematology Oncology Department, Ospedali Riuniti, Bergamo, Italy
    Pathophysiol Haemost Thromb 33:19-21. 2003
  26. ncbi Venous thromboembolism in oncology
    Anna Falanga
    Department of Hematology Oncology, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Eksp Onkol 26:11-4. 2004
    ....
  27. ncbi The effect of anticoagulant drugs on cancer
    A Falanga
    Department of Hematology Oncology, Ospedali Riuniti, Bergamo, Italy
    J Thromb Haemost 2:1263-5. 2004
  28. ncbi Biological and clinical aspects of anticancer effects of antithrombotics
    Anna Falanga
    Department of Hematology Oncology, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Pathophysiol Haemost Thromb 33:389-92. 2003
    ..More recently a number of prospective randomized clinical trials of LMWH for survival as a primary end-point in cancer patients have been conducted, showing favourable results...
  29. ncbi Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera
    A Falanga
    Hematology Division, Ospedali Riuniti, Bergamo, Italy
    Blood 96:4261-6. 2000
    ..Blood. 2000;96:4261-4266)..
  30. ncbi All-trans retinoic acid modulates microvascular endothelial cell hemostatic properties
    Marina Marchetti
    Hematology Department, Ospedali Riuniti Bergamo, Largo Barozzi, 1, 24128 Bergamo, Italy
    Haematologica 88:895-905. 2003
    ..In this study we investigated whether ATRA may affect the same activities of EC derived from microvessels (HMEC-1 cell line)...
  31. doi All trans-retinoic acid modulates the procoagulant activity of human breast cancer cells
    Marina Marchetti
    Division of Immunohematology and Transfusion Medicine, Department of Oncology Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Thromb Res 128:368-74. 2011
    ..Due to the pivotal role of coagulation activation in tumor progression, the capacity of ATRA to affect also tumor procoagulants, in parallel to cell apoptosis, open new perspectives in tumor therapy...
  32. doi ADP-induced platelet aggregation and thrombin generation are increased in Essential Thrombocythemia and Polycythemia Vera
    Marina Panova-Noeva
    Division of Immunohematology and Transfusion Medicine, Ospedale Papa Giovanni XXIII, Bergamo, Italy
    Thromb Res 132:88-93. 2013
    ..The aim of this study was to characterize the platelet aggregation as well as the platelet procoagulant potential induced by several different agonists in ET and PV patients...
  33. ncbi Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin
    Marina Marchetti
    Department of Hematology, Ospedali Riuniti di Bergamo, Largo Barozzi, 1 24128 Bergamo, Italy
    Thromb Res 121:637-45. 2008
    ..Clinical studies suggest a survival advantage in cancer patients receiving low molecular weight heparin (LMWH). A suggested mechanism for this beneficial effect may reside in the antiangiogenic activity of heparins...
  34. doi JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients
    Marina Panova-Noeva
    Division of Immunohematology and Transfusion Medicine, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Blood 118:2599-601. 2011
    ..The second finding is that IPF is susceptible to myelosuppressive treatment, which may additionally explain the favorable effect of hydroxyurea therapy on MPN outcome as well as the associated thrombotic risk...
  35. pmc Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with essential thrombocythemia
    Marina Marchetti
    Division of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy
    Am J Hematol 89:68-73. 2014
    ..No difference was seen between the thrombosis and no thrombosis group. Prospective studies are needed to test whether MP-associated thrombin generation and procoagulant activity may predict for thrombosis in these patients...
  36. doi LMWH bemiparin and ULMWH RO-14 reduce the endothelial angiogenic features elicited by leukemia, lung cancer, or breast cancer cells
    Alfonso Vignoli
    Division of Immunohematology and Transfusion Medicine, Department of Oncology Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Cancer Invest 29:153-61. 2011
    ..Both drugs also inhibited angiogenic response elicited by purified VEGF and FGF-2. These findings support a possible role of these molecules as adjuvant drugs in cancer treatment...
  37. pmc Characterization of the thrombin generation potential of leukemic and solid tumor cells by calibrated automated thrombography
    Marina Marchetti
    Division of Immunohematology and Transfusion Medicine, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Haematologica 97:1173-80. 2012
    ..In this study we applied a single global coagulation test, the calibrated automated thrombogram assay, to characterize the specific procoagulant phenotypes of different tumor cells...
  38. ncbi Differential effect of the low-molecular-weight heparin, dalteparin, and unfractionated heparin on microvascular endothelial cell hemostatic properties
    Alfonso Vignoli
    Department of Hematology Oncology, Ospedali Riuniti di Bergamo, Largo Barozzi 1, 24128 Bergamo, Italy
    Haematologica 91:207-14. 2006
    ..e. dalteparin, with UFH on both microvascular (human microvascular endothelial cells [HMEC-1]) and macrovascular (human umbilical vein endothelial cells [HUVEC]) endothelial cells...
  39. ncbi Effect of anticoagulant drugs in cancer
    Anna Falanga
    Division of Hematology, Department of Hematology Oncology, Ospedali Riuniti, Bergamo, Italy
    Curr Opin Pulm Med 11:403-7. 2005
    ....
  40. doi Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms
    Giuseppe Cella
    Division of Immunohematology and Transfusion Medicine and Hemostasis and Thrombosis Center, Ospedali Riuniti, Bergamo, Italy
    Thromb Haemost 104:151-6. 2010
    ..Our data demonstrate that ET and PV are characterised by an altered pattern of soluble selectins and NOX. HU-mediated increase of NOX levels could represent an additional antithrombotic mechanism of this drug...
  41. ncbi 45th annual meeting of the Italian Cancer Society. Bergamo, 9-12 November 2003
    Raffaella Giavazzi
    Dipartimento di Oncologia, Istituto di Ricerche Farmacologiche Mario Negri, Bergamo, Italy
    Tumori 90:356-62. 2004
    ..We hope that the following report gives an idea of the event and will encourage the reader to attend the 46th meeting of the SIC, 24-26 October, 2004 in Pisa...
  42. doi Platelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera
    Marina Panova-Noeva
    Division of Immunohematology and Transfusion Medicine, Ospedali Riuniti di Bergamo, Largo Barozzi 1, Bergamo, Italy
    Am J Hematol 86:337-42. 2011
    ..05).This study demonstrates a platelet-dependent form of hypercoagulability in MPN patients, particularly in those carriers of the JAK2V617F mutation. The cytoreductive therapy with HU significantly affects this prothrombotic phenotype...
  43. doi Procoagulant mechanisms in tumour cells
    Anna Falanga
    Haemostasis and Thrombosis Centre, Department of Haematology Oncology, Ospedali Riuniti Bergamo, Largo Barozzi n 1, Bergamo 24128, Italy
    Best Pract Res Clin Haematol 22:49-60. 2009
    ..In particular, this chapter will focus on the capacity of tumour cells to promote activation of the coagulation system, and on the mechanisms by which clotting proteins may promote tumour growth and metastasis...
  44. ncbi Treatment of thromboembolism in cancer patients
    Marina Panova-Noeva
    Division of Immunohematology and Transfusion Medicine, Department of Oncology Hematology, Ospedali Riuniti di Bergamo, 24128 Bergamo, Italy
    Expert Opin Pharmacother 11:2049-58. 2010
    ..The management of VTE in cancer patients is challenging because the anticoagulant treatment in these patients can be less effective and carry considerable morbidity...
  45. ncbi Mechanisms of thrombosis in cancer
    A Falanga
    Division of Hematology, Ospedali Riuniti di Bergamo, Italy
    Thromb Res 115:21-4. 2005
  46. pmc Tissue Factor Expression on Platelet Surface during Preparation and Storage of Platelet Concentrates
    Alfonso Vignoli
    Division of Immunohematology and Transfusion Medicine, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
    Transfus Med Hemother 40:126-32. 2013
    ..The present study evaluated, for the first time, the expression of TF on platelet surface during preparation and storage of platelet concentrates (PC) for transfusional use...
  47. ncbi Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells
    A Falanga
    Department of Hematology, Ospedali Riuniti, Bergamo, Italy
    Leukemia 17:1636-42. 2003
    ..Decreasing the procoagulant activity and increasing the fibrinolytic potential of EC favors an anticoagulant phenotype of the endothelium, which may protect from fibrin deposition and vascular occlusion...
  48. ncbi Thrombosis and malignancy: an underestimated problem
    Anna Falanga
    Hematology Department, Ospedali Riuniti, Bergamo, Italy
    Haematologica 88:607-10. 2003
  49. doi Management of venous thromboembolism in cancer patients: ESMO clinical recommendations
    M Mandala
    Unit of Medical Oncology, Ospedali Riuniti, Bergamo, Italy
    Ann Oncol 19:ii126-7. 2008
  50. ncbi Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM)
    M Mandala
    Division of Medical Oncology, Azienda Ospedaliera Treviglio Caravaggio, Treviglio Caravaggio Hospital P le Ospedale 1, 24047 Treviglio, Bergamo, Italy
    Crit Rev Oncol Hematol 59:194-204. 2006
    ....
  51. ncbi The coagulopathy of cancer
    Anna Falanga
    Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy
    Curr Opin Hematol 21:423-9. 2014
    ..Also, to offer an update of the recent progresses in the risk assessment, prevention, and treatment of thrombohemorrhagic complications in cancer patients...
  52. ncbi Thrombosis in myeloproliferative neoplasms
    Anna Falanga
    Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy
    Semin Thromb Hemost 40:348-58. 2014
    ..Finally, a better understanding of the molecular events leading to the progress of the hypercoagulable state in MPN patients may provide appropriate tools for the development of targeted therapies based on reversal of coagulopathy. ..
  53. pmc Pathogenesis and treatment of thrombohemorrhagic diathesis in acute promyelocytic leukemia
    Anna Falanga
    Division of Immunohematology and Transfusion Medicine, Dept Oncology Hematology, Ospedali Riuniti, Bergamo, Italy
    Mediterr J Hematol Infect Dis 3:e2011068. 2011
    ..In this review, we will summarize our current knowledge of the pathogenesis of the APL-associated coagulopathy and will overview the therapeutic approaches for the management of this complication...
  54. ncbi Pathogenesis of thrombosis in patients with malignancy
    A Falanga
    Hematology Division, Ospedali Riuniti, Bergamo, Italy
    Int J Hematol 73:137-44. 2001
    ..We hope that better knowledge of these pathogenetic pathways will lead to the development of more targeted strategies to prevent thromboembolism in cancer patients...
  55. doi Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial
    M Mandala
    Department of Oncology and Hematology, Ospedali Riuniti di Bergamo, Largo Barozzi 1, Bergamo, Italy
    Ann Oncol 21:871-6. 2010
    ..Acquired and inherited risk factors for venous thromboembolism (VTE) and the incidence of symptomatic VTE were investigated in patients on adjuvant chemotherapy for breast or gastrointestinal cancer (GI)...
  56. ncbi Disseminated intravascular coagulation in acute leukemia
    T Barbui
    Hematology Department, Ospedali Riuniti, Bergamo, Italy
    Semin Thromb Hemost 27:593-604. 2001
    ....
  57. ncbi All-trans-retinoic acid increases adhesion to endothelium of the human promyelocytic leukaemia cell line NB4
    M Marchetti
    Haematology Department, Osepadali Riuniti, Bergamo, Italy
    Br J Haematol 93:360-6. 1996
    ..These findings parallel the increment of NB4 surface adhesive molecules, among which VLA4 and LFA1 appear to play an important part. These mechanisms may contribute to the complications of ATRA therapy in APL...
  58. ncbi The extension of disease is associated to an increased risk of venous thromboembolism (VTE) in patients with gastrointestinal (GI) carcinoma
    Mario Mandala
    Thromb Haemost 95:752-4. 2006
  59. ncbi Catheter-related thrombosis in hematologic patients
    Marco Moia
    Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Department of Hematology, IRCCS Maggiore Hospital and University of Milan, Milan, Italy
    Rev Clin Exp Hematol 8:E5. 2004
    ..However, more studies are still needed to address this issue. This review will focus on CVC use and complications in oncohematologic patients...
  60. ncbi Anticoagulants and cancer survival
    Andrea Piccioli
    Department of Medical and Surgical Sciences, Department of Internal Medicine, University of Padova, Italy
    Semin Thromb Hemost 32:810-3. 2006
    ..Additional clinical trials are needed to provide an important step forward in this challenging setting...
  61. ncbi Meeting report. Acute promyelocytic leukemia-associated coagulopathy, 21 January 2004, London, United Kingdom
    Martin S Tallman
    Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Centre, 676 N St Clair Street, Suite 850, Chicago, IL 60611, USA
    Leuk Res 29:347-51. 2005
    ..Eight speakers participated in the workshop. This meeting report provides synopses of their presentations and a summary of highlights from the meeting...
  62. ncbi Cancer and venous thromboembolism
    Paolo Prandoni
    Department of Medical and Surgical Sciences, Second Chair of Internal Medicine, University of Padua, Padua, Italy
    Lancet Oncol 6:401-10. 2005
    ..However, the issue of whether screening for occult malignant disease ultimately improves prognosis and survival remains to be resolved...
  63. ncbi Thrombotic problems in hematologic malignancies
    Anna Falanga
    Rev Clin Exp Hematol 8:1 p preceding E1. 2004
  64. ncbi Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study
    Agostino Cortelezzi
    Department of Haematology and Bone Marrow Transplantation Unit, IRCCS Fondazione Ospedale Maggiore Policlinico and University of Milan, Milan, Italy
    Br J Haematol 129:811-7. 2005
    ..This study shows that the impact on clinical practice of symptomatic CVC-related thrombotic complications is not negligible in patients with haematological malignancies...
  65. ncbi American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer
    Gary H Lyman
    Duke University Medical Center, University of Rochester Medical Center, Rochester, USA
    J Clin Oncol 25:5490-505. 2007
    ..To develop guideline recommendations for the use of anticoagulation in the prevention and treatment of venous thromboembolism (VTE) in patients with cancer...